Mastercard signs worldwide reseller agreement for Rezolve Ai commerce software
Bitget2026/10/05 12:10Rezolve Ai entered a worldwide, non-exclusive reseller agreement with Mastercard to distribute its AI-powered commerce software and SaaS subscriptions. Mastercard will lead sales coordination, contract directly with resale customers, and market the products globally as a new channel for Rezolve Ai. Deal targets AI-driven shopping, covering conversational commerce, intelligent search, personalization, and checkout orchestration. Commercial terms will be set deal-by-deal through separate statements of work, including scope, geography, and selected capabilities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolve Ai plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839487) on October 05, 2026, and is solely responsible for the information contained therein.
- Rezolve Ai entered a worldwide, non-exclusive reseller agreement with Mastercard to distribute its AI-powered commerce software and SaaS subscriptions.
- Mastercard will lead sales coordination, contract directly with resale customers, and market the products globally as a new channel for Rezolve Ai.
- Deal targets AI-driven shopping, covering conversational commerce, intelligent search, personalization, and checkout orchestration.
- Commercial terms will be set deal-by-deal through separate statements of work, including scope, geography, and selected capabilities.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Pimco warns: 10-year US Treasury yield may hit 6%, for the first time since 2000
PIMCO's Chief Investment Officer stated that due to high oil prices intensifying inflation concerns and market unease over the growing U.S. public debt, the benchmark 10-year U.S. Treasury yield could rise to 6% for the first time since 2000.
Crypto prices
More
